In this presentation from Lymphoma & Myeloma 2016, Dr. Swaminathan P. Iyer discusses novel agents in the pipleine for the…
Browsing: Acute Lymphoblastic Leukemia
In this presentation from Lymphoma & Myeloma 2016, Dr. John N. Allan provides an update on Richter’s syndrome. Click to…
In this presentation from Lymphoma & Myeloma 2016, Dr. Neil E. Kay discusses optimal approaches for the management of chronic…
Stephen J. Russell, MD, PhD of Mayo Clinic discusses how viral therapy results will trigger a race to complete clinical…
Stephen J. Russell, MD, PhD of Mayo Clinic explains why viral therapy may prove to be a transformational addition to…
Stephen J. Russell, MD, PhD of Mayo Clinic explains why recombinant measles and recombinant vesicular stomatitis virus are ideal adjunct…
Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute discusses how stress reducing beta blockers combined with immunotherapy may increase…
Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute explains how patients on beta blockers may do better with immunotherapy…
Elizabeth A. Repasky, PhD of Roswell Park Cancer Institute gives an overview of her presentation that was presented at ASCO-SITC…
Graham P. Pawelec, PhD of Universitätsklinikum Tübingen explains how new data suggests immunosenescence may not be a factor in immunotherapy…
Heather McArthur, MD of Cedars-Sinai Medical Center discusses the importance of combination strategies in treatment for negative breast cancer. Specifically,…
Heather McArthur, MD of Cedars-Sinai Medical Center discusses the most interesting research she has seen at the ASCO-SITC Symposium. This…
Heather McArthur, MD of Cedars-Sinai Medical Center gives an overview of a poster discussion that was presented at the ASCO-SITC…
Heather McArthur, MD of Cedars-Sinai Medical Center discusses a Phase 1 Study that was being presented at ASCO-SITC. This study…
Heather McArthur, MD of Cedars-Sinai Medical Center discusses the importance of checkpoint blockade in breast cancer. With the biomarker PDL-1,…
James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses promising approaches for looking…
James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health discusses the new research regarding…
James L. Gulley, MD, PhD of National Cancer Institute at the National Institutes of Health gives an overview of the…
Claire Friedman, MD of Memorial-Sloan Kettering talks about the different types of combinations in immunotherapy. She suggests that two combined…
Claire Friedman, MD of Memorial-Sloan Kettering advises healthcare professionals to use Nivolumab and Ipilimumab in treating patients with advanced melanoma,…
Claire Friedman, MD of Memorial-Sloan Kettering discusses the importance of novel combinations for immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium…
Claire Friedman, MD of Memorial-Sloan Kettering discusses the use of combination therapy for patients with melanoma at the ASCO-SITC Clinical…
Lawrence Fong, MD of University of California, San Francisco discusses the use of more combinations therapies, like Nivolumab and Ipilimumab.…
Lawrence Fong, MD of University of California, San Francisco explains how there are several combination therapies to study, but not…
Lawrence Fong, MD of University of California, San Francisco discusses upcoming combination therapies for melanoma treatment that will be FDA…
Ezra E.W. Cohen, MD of University of California, San Diego explains how immunotherapy is expanding for cancer treatment into new…
Ezra E.W. Cohen, MD of University of California, San Diego states that in 2017, we will see more combination immuno-therapy…
Ezra E.W. Cohen, MD of University of California, San Diego explains how biomarkers and combination therapy may be the path…
Ezra E.W. Cohen, MD of University of California, San Diego gives an overview of presentations that were discussed at ASCO-SITC.…
Stephen M. Ansell, MD, PhD of Mayo Clinic discusses the abstracts and new data that were presented at the second…
Stephen M. Ansell, MD, PhD of Mayo Clinic discusses the promising and exciting new results from CAR T-Cell data for…
Keith Argenbright, MD of UT Southwestern Medical Center discusses the geographical barriers for cancer survivorship. In these undeserved areas, which…
Keith Argenbright, MD of UT Southwestern Medical Center discusses his presentation “Driving Survivorship Home,” which was presented at ASCO’s 2017…
Keith Argenbright, MD of UT Southwestern Medical Center explains how he finds patients for his Mobile Survivorship program. He states…
Keith Argenbright, MD of UT Southwestern Medical Center discusses the advantages of a mobile survivorship program. He states that there…
Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses the research he found most intriguing…
Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses how radiation has changed for invasive…
Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses which patients with low-risk prostate cancer…
Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University explains the difference between the side effects…
Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University diseases how the use of radiation has…
Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University gives an overview of his presentation “Best…
Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains his perspective on how to integrate…
Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains how treatment for prostate cancer has…
Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains how and when immunotherapy will be…
Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada discusses how the clinical trials, CHAARTED and…
Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada discusses when and where does chemotherapy fit…
Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains why he believes that all metastatic…
Nicholas J. Vogelzang, MD, FAnnual Meeting, FACP of Comprehensive Cancer Centers of Nevada explains why BRCA 1 and BRCA 2…
Ulka N. Vaishampayan, MD of Karmanos Cancer Institute explains what the biggest challenges are in facing patients and providers in…
Ulka N. Vaishampayan, MD of Karmanos Cancer Institute discusses how immunotherapies are being integrated renal cell carcinoma treatment. She states…